The study, led by Professor Anne May, a distinguished Clinical Epidemiologist specialized in Cancer Survivorship at the University Medical Center Utrecht and the Netherlands Cancer Institute, specifically targeted patients with stage IV metastatic breast cancer. This cohort, often experiencing debilitating side effects including fatigue, nausea, pain, and muscle wasting, was enrolled in a comprehensive nine-month exercise program designed to address declines in skeletal muscle mass and functional capacity. The exercise intervention combined aerobic, resistance, and balance training, tailored and supervised by expert trainers to suit individual patient capabilities and treatment statuses.

Skeletal muscle mass, particularly in the arms and legs, is critically linked to mobility, functional independence, and resistance to falls—concerns acutely magnified in breast cancer patients with metastatic spread, especially those with bone metastases. The PREFERABLE-EFFECT study intricately measured whole-body lean mass, a primary indicator of muscle health, and found that participants undergoing supervised exercise experienced an average increase of 0.79 kilograms after three months and maintained a muscle mass retention advantage at six months compared to controls. These findings represent a pivotal shift from previous assumptions that advanced cancer and its treatments irreversibly diminish physical function and muscle integrity.

Notably, the study’s rigorous randomized controlled design spanned multiple international centers, including Germany, Poland, Spain, Sweden, The Netherlands, and Australia, enrolling 357 participants between 2019 and 2022. Such diversity enhances the generalizability of the results, reflecting a broad spectrum of metastatic breast cancer patients mostly undergoing first or second-line therapies. Importantly, most participants presented with bone metastases, a factor compounding their risk for fractures and functional decline, thereby underscoring the critical nature of the exercise intervention’s impact on balance and musculoskeletal strength.

Muscle mass gains observed were not uniform throughout the body but concentrated in limbs instrumental for daily activities and weight-bearing functions. The study reports statistically significant improvements in skeletal muscle mass index (SMI), an analogue to body mass index for musculature, with increases of 0.22 kg/m^2 at three months and sustained improvement at six months in the exercise group. Conversely, the control group experienced declines in both muscle mass and SMI, highlighting the natural trajectory of muscle degradation in untreated metastatic breast cancer patients.

Beyond mass accrual, functional assessments revealed enhanced physical performance, including improved balance and muscle strength, which directly correlate with decreased fall risk. This is especially salient given that neuropathy induced by chemotherapy can exacerbate balance deficits and frailty. One patient’s anecdote vividly illustrates these gains—initial incapacity to safely use public transportation was reversed through commitment to the exercise program, enabling renewed community engagement and autonomy.

While the exercise intervention robustly augmented lean muscle mass and strength, no significant differences were observed between groups in terms of whole-body fat percentage. This specificity suggests that exercise predominantly mitigates cancer-and-therapy-induced muscle wasting rather than inducing broad body composition shifts, a nuanced finding that informs future intervention targets.

The mechanistic underpinnings of these improvements likely extend beyond physiological alterations alone. Strengthened musculature is associated with better treatment tolerability, potentially reducing the incidence of dose-limiting toxicities and enabling adherence to full therapeutic regimens. Additionally, increased muscle strength has been linked to improved survival outcomes and enhanced quality of life metrics, encompassing physical, psychological, and social dimensions for patients often facing chronic disease trajectories.

This study represents a significant paradigm shift. Historically, patients with metastatic breast cancer were frequently excluded from exercise trials due to concerns about safety and efficacy. The PREFERABLE-EFFECT study’s success challenges this notion, advocating for the integration of supervised, comprehensive exercise programs as standard-of-care components. The resistance training element is especially emphasized, given its effectiveness in combating muscle atrophy.

Looking forward, the ABC Global Alliance plans to launch a Physical Activity Resource Hub by early 2026, providing tailored exercise resources for patients, caregivers, and healthcare professionals. This digital platform will incorporate instructional videos, customizable exercise guides, and evidence-based guidance to accommodate varying metastases locations, symptom burdens, and fitness levels. The initiative is spearheaded by experts including cancer physiotherapist Isabelle Aloi-Timeus and patient advocate Eva Schumacher-Wulf, ensuring the hub’s practicality and relevance.

The broader oncology community and cancer care providers increasingly recognize that effective cancer management encompasses not only oncologic control but also the preservation and enhancement of functional status and life quality. Professor Fatima Cardoso, President of ABC Global Alliance, underscores this ethos, emphasizing that empowering patients through supervised exercise constitutes a vital therapeutic adjunct, enabling patients to regain agency over their health and daily lives.

In sum, the PREFERABLE-EFFECT study solidifies the role of exercise as a potent, evidence-based intervention mitigating muscle wasting, enhancing physical performance, and ultimately improving the lived experience of patients with metastatic breast cancer. This milestone advances a holistic model of cancer care, positioning physical activity as indispensable in the continuum of treatment and survivorship.

Subject of Research: People

Article Title: Exercise and body composition

News Publication Date: 7-Nov-2025

References:

[1] Anne May, “Exercise and body composition”, Presentation at the Advanced Breast Cancer Eighth International Consensus Conference (ABC8), 7 November 2025.

[2] PREFERABLE-EFFECT study: Project on Exercise for Fatigue Eradication in Advanced Breast to improve quality of Life – Effects of exercise in patients with metastatic breast cancer.

Image Credits: Anne May

Keywords: Breast cancer, Breast carcinoma, Cancer, Cancer relapse, Health care, Physical exercise, Health counseling

Sarcopenia’s insidious nature lies in its subtlety; muscle deterioration develops gradually and often goes unnoticed until it culminates in significant functional impairment. For breast cancer patients, this decline can be compounded by the metabolic and physiological stresses imposed by cancer itself and its therapies. The need for reliable, easy-to-administer screening tools is crucial, as early detection of sarcopenia risk could facilitate timely interventions aimed at preserving muscle health and improving overall prognosis. To this end, the study meticulously compared three established instruments—SARC-F, SARC-CalF, and the BMI-adjusted SARC-CalF—in their ability to detect sarcopenia risk among women recently diagnosed with breast cancer.

The investigative team recruited 168 women progressing through their first year post-breast cancer diagnosis, with a mean age of approximately 55 years, to assess the practicality and accuracy of these screening tools. Sarcopenia was strictly defined according to the European Working Group on Sarcopenia in Older People’s updated criteria (EWGSOP2), which combine objective metrics of muscle strength—measured via handgrip dynamometry—with appendicular skeletal muscle mass index assessed using dual-energy X-ray absorptiometry (DXA), ensuring a robust diagnostic standard.

Analyses revealed striking disparities in the prevalence rates of sarcopenia risk identified by each tool. While the SARC-F instrument, a quick questionnaire-based assessment, flagged roughly 10% of participants at risk, its counterpart, SARC-CalF, which incorporates calf circumference, identified over a third (36.6%)—a considerable difference highlighting the impact of anthropometric augmentation in screening. Meanwhile, the BMI-adjusted SARC-CalF, which further refines risk stratification by factoring in body mass index, produced intermediate estimates but with diminished diagnostic robustness.

When benchmarked against the strict EWGSOP2 sarcopenia diagnosis, the SARC-CalF emerged as the superior screening tool, boasting an area under the receiver operating characteristic curve (AUC) of 0.79—indicative of good discriminative ability. This contrasts sharply with SARC-F’s AUC of approximately 0.55 and BMI-adjusted SARC-CalF’s borderline 0.52, neither of which performed statistically better than chance. Notwithstanding this relative performance, SARC-CalF’s sensitivity remained modest at 42.8%, implying that over half of sarcopenia cases could be overlooked if relying solely on this tool for screening.

Specificity metrics painted a more favorable picture: SARC-CalF excelled at correctly identifying those without sarcopenia risk, achieving a high specificity of over 92%. This attribute minimizes false-positive results, a critical consideration in clinical settings where unwarranted diagnostic evaluations can impose psychological and economic burdens. In contrast, the BMI-adjusted SARC-CalF yielded specificity around 63%, considerably lower and less reliable for ruling out sarcopenia.

These findings underscore the inherent trade-offs in sarcopenia screening. While anthropometric enhancements such as calf circumference measurement improve SARC-F’s predictive power, adjusting for body mass index paradoxically attenuates accuracy, perhaps due to BMI’s inability to distinguish between lean mass and adiposity effectively in cancer patients who may experience fluctuating body composition. The nuanced interactions between muscle wasting, fat distribution, and cancer pathology complicate simplistic screening algorithms.

Beyond statistical performance, the clinical implications of these results are profound. Breast cancer survivors are a heterogeneous group: varying in age, treatment regimens, comorbidities, and lifestyle factors—all influencing muscle health trajectories. Employing an imperfect screening tool risks underdiagnosis and missed opportunities for intervention, yet utilizing overly sensitive instruments may strain healthcare resources and divert attention from other needs.

Therefore, the study’s authors advocate a cautious approach. Despite SARC-CalF’s relative superiority, its limited sensitivity signals the need for comprehensive sarcopenia assessment protocols incorporating both clinical judgment and objective measurements. This may entail integrating screening tools with biochemical markers, imaging techniques, and functional performance tests, tailored to the oncology rehabilitation context.

The study further prompts reconsideration of universal screening instruments for sarcopenia in specialized populations. Breast cancer’s unique catabolic milieu, influenced by cytokine profiles, hormonal changes, and cytotoxic treatments, demands customized assessment strategies rather than one-size-fits-all tools developed primarily for community-dwelling older adults. Investigations into novel biomarkers and novel digital health technologies for muscle monitoring could revolutionize early diagnosis and individualized care.

This research also highlights the urgent necessity for interdisciplinary collaboration. Oncologists, geriatricians, physiotherapists, and nutritionists must coalesce to devise and validate multifactorial screening paradigms that address sarcopenia’s multifaceted etiology in cancer populations. Interventional studies focusing on resistance training, nutritional supplementation, and pharmacological agents targeting muscle anabolism will further clarify how screening translates to meaningful outcomes.

Moreover, the modest size and cross-sectional design of the study invite further longitudinal research encompassing diverse ethnicities and treatment modalities to establish generalizability and causality. Understanding how sarcopenia risk evolves over the breast cancer care continuum will empower healthcare providers to stratify patients dynamically and optimize resources.

In conclusion, this rigorous comparative analysis marks a significant advance in recognizing the challenges posed by sarcopenia among women with breast cancer. While SARC-CalF currently offers the best available option among simple screening tools, its limitations underscore the imperative for refined instruments and multifaceted assessment approaches. As research continues to elucidate sarcopenia’s complex interplay with cancer biology and survivorship, integrating precise and practical screening into routine oncological care could profoundly improve functional outcomes and quality of life for countless women worldwide.

Subject of Research: Risk assessment of sarcopenia in women with breast cancer using comparative analysis of screening tools.

Article Title: Risk of sarcopenia in women with breast cancer: a comparative analysis of screening tools

Article References:
de Souza Mamede, V.F., Bernabé, R.d.M., Santos, T.G. et al. Risk of sarcopenia in women with breast cancer: a comparative analysis of screening tools. BMC Cancer 25, 839 (2025). https://doi.org/10.1186/s12885-025-14062-7

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-14062-7

Comprising a vast cohort of 20,292 women aged 65 and older with stage I to stage III breast cancer, the study meticulously tracked the frailty trajectories of participants following the initiation of adjuvant chemotherapy. Researchers determined that a concerning 4.5% of the cohort experienced nonresilient frailty trajectories, indicating a marked decline in their physiological reserves post-chemotherapy. Strikingly, those women classified within this nonresilient category demonstrated significantly worse survival rates when compared to their counterparts who either maintained stable frailty levels or exhibited improvements over time.

The study’s implications extend beyond the immediate survival outcomes associated with chemotherapy, revealing critical insights into the long-term health of older women with breast cancer. Notably, those patients who were able to sustain their physical strength or recover from temporary declines enjoyed markedly better survival rates. This correlation between frailty management and improved outcomes highlights a pivotal area for further investigation and sociomedical intervention in geriatric oncology.

One of the more alarming revelations from the research was the heightened mortality rate among women undergoing nonresilient frailty trajectories. Although representing a minority of the larger cohort, this group experienced significantly increased mortality, indicating that managing frailty should be a priority for healthcare providers, particularly in the oncology setting. Health practitioners are thus encouraged to employ integrated care strategies that address not only the cancer but also the overall well-being of their patients.

Importantly, tracking frailty over time has proven useful for identifying overarching survival trends within patient groups, yet researchers cautioned against its effectiveness as a predictive tool for individual patient outcomes. The study prompted questions about the ability to customize patient care based on individual frailty assessments, which is a crucial consideration in the treatment of older adults who often present with a multitude of comorbid conditions.

Furthermore, the implications of this research extend to future studies aimed at exploring whether frailty changes correlate with other significant health outcomes, such as the incidence of falls or hospitalizations. In this regard, understanding the nuances of frailty can equip healthcare providers with invaluable insights to preemptively address potential complications and incorporate necessary interventions. For instance, targeted strategies that include nutritional support, physical activity enhancements, and comprehensive management of chemotherapy-related side effects could be essential in mitigating the risks associated with frailty.

The researchers emphasized the importance of longitudinal studies that monitor frailty trajectories over the course of cancer treatment. By closely assessing these changes, healthcare providers can adapt their treatment plans to meet the evolving needs of their patients. This proactive approach could ultimately lead to improved survival rates and enhanced quality of life for older women navigating the challenges of breast cancer treatment.

Dae Hyun Kim, MD, MPH, ScD, who contributed significantly to the study, articulated the findings eloquently. “Our research demonstrates that frailty is not a static condition but can change over time, especially during cancer treatment,” he stated. His commentary highlights the transformative potential of individualized treatment modalities that take into account not just the cancer but the frail state of the patient.

As the study continues to garner attention, the findings resonate across a broad spectrum of stakeholders in the healthcare field, particularly among geriatricians, oncologists, and nursing staff. The emphasis on frailty as a dynamic entity rather than a fixed state may shift traditional paradigms in cancer care, encouraging a more holistic view that encompasses physical, emotional, and psychological health.

Over the coming years, the objective will be to articulate clearer guidelines for assessing frailty among elderly cancer patients. Developing robust frameworks that allow for timely interventions could be the key to shaping a more effective healthcare delivery model. This will require a concerted effort among researchers, clinicians, and policymakers to prioritize the integration of frailty assessments into standard oncological evaluations.

Ultimately, as the population ages, the challenge of managing frailty among older cancer patients will grow increasingly paramount. This study acts as a clarion call to the medical community to take urgent action in refining approaches to care that are responsive to the realities of aging and chronic disease. As we continue to uncover the intricate relationships between frailty and cancer outcomes, fostering interdisciplinary collaboration within the healthcare sector will be essential to optimize patient care and ensure a dignified aging process for our elderly population.

The study’s findings are a step toward a greater understanding of frailty in the context of cancer treatment and may have profound implications for the management of chronic conditions in older adults. Future research will be vital in advancing knowledge in this area and ensuring that treatment strategies align with the lived experiences of older patients facing daunting health challenges.

In closing, this research serves as an important reminder that as we strive for advances in cancer therapies, we must also pay close attention to the holistic dimensions of patient care. By addressing frailty actively, healthcare providers can improve survival rates, enhance patient well-being, and ultimately transform the oncology treatment landscape for older women with breast cancer.

Subject of Research: Frailty Trajectories in Elderly Women with Breast Cancer
Article Title: Frailty Trajectories Following Adjuvant Chemotherapy and Mortality in Older Women With Breast Cancer
News Publication Date: 12-Mar-2025
Web References: https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2831318
References: N/A
Image Credits: N/A
Keywords: Breast Cancer, Frailty, Chemotherapy, Older Women, Survival Outcomes, Geriatric Oncology, Healthcare Interventions, Physiological Reserves, Aging Research.